Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients.

摘要: Objectives To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in CD133 (rs2240688A>C, rs10022537T>A, rs7686732C>G, and rs3130C>T) on overall survival (OS) non-small cell lung cancer (NSCLC) patients. Design Retrospective cohort study. Setting Department General Surgery, a general hospital, Henan Province, China. Participants NSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies had blood sample available for genotyping, eligible inclusion. Those participants pregnant or breastfeeding, previous history cancer, other primary tumours, tumours skin nasopharynx, excluded from Outcome measures The endpoint was OS, which calculated date enrolment until death last follow-up. Results There total 1383 participants, with median age 63 years; 726 (52.5%) male. Compared thers2240688 AA genotype, variant AC/CC genotypes independently associated OS (HR 1.27, 95% CI 1.12 to 1.45 AC genotype; HR 2.32, 95% CI 1.91 2.80 CC genotype). Higher hazard ratios associations between rs2240688 polymorphism observed adjuvant chemotherapy 1.86, 1.52 2.26) radiotherapy curative intent 1.90, 1.55 2.33). Conclusions study confirmed significant association SNP A>C Larger population-based studies different ethnic groups are necessary further validate role mechanisms NSCLC.